Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC)

被引：3
|
作者：
Morizane, Chigusa
Ueno, Makoto
Sasaki, Takashi
Nagashima, Fumio
Mizuno, Nobumasa
Shimizu, Satoshi
Hayata, Nozomi
Ikezawa, Hiroki
Suzuki, Takuya
Nakajima, Ryo
Dutcus, Corina E.
Ikeda, Masafumi
机构：
[1] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[2] Kanagawa Canc Ctr Hosp, Div Hepatobiliary & Pancreat Oncol, Yokohama, Kanagawa, Japan
[3] Canc Inst Hosp JFCR, Tokyo, Japan
[4] Kyorin Univ, Dept Med Oncol, Tokyo, Japan
[5] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi, Japan
[6] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[7] Eisai & Co Ltd, Tokyo, Japan
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.310
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
310
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
    Yi, Jun Ho
    Thongprasert, Sumitra
    Lee, Jeeyun
    Doval, D. C.
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 196 - 201
  • [22] Second-line chemotherapy in patients with advanced biliary tract cancer
    Takahara, Naminatsu
    Nakai, Yousuke
    Isayama, Hiroyuki
    Sasaki, Takashi
    Ishigaki, Kazunaga
    Saito, Kei
    Mizuno, Suguru
    Kogure, Hirofumi
    Tada, Minoru
    Koike, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [23] Second-line FOLFOX chemotherapy for advanced biliary tract cancer
    Lamarca, Angela
    Palmer, Daniel H.
    Wasan, Harpreet Singh
    Ross, Paul J.
    Ma, Yuk Ting
    Arora, Arvind
    Falk, Stephen
    Gillmore, Roopinder
    Wadsley, Jonathan
    Patel, Kinnari
    Anthoney, Alan
    Maraveyas, Anthony
    Iveson, Tim
    Waters, Justin S.
    Hobbs, Claire
    Barber, Safia
    David Ryder, W.
    Ramage, John
    Davies, Linda M.
    Bridgewater, John A.
    Valle, Juan W.
    LANCET ONCOLOGY, 2021, 22 (07): : E288 - E289
  • [24] Second-line chemotherapy in patients with biliary tract cancer.
    Brandi, G.
    Di Girolamo, S.
    de Rosa, F.
    Corbelli, J.
    Agostini, V.
    Garajova, I.
    Longobardi, C.
    Paragona, M.
    Ercolani, G.
    Pinna, A. D.
    Biasco, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase II study of S-1 in patients with unresectable or recurrent biliary tract cancer (BTC)
    Boku, N.
    Okusaka, T.
    Furuse, J.
    Ohkawa, S.
    Yamao, K.
    Masumoto, T.
    Funakoshi, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 318 - 318
  • [26] A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Takahara, Naminatsu
    Akiyama, Dai
    Yagioka, Hiroshi
    Kogure, Hirofumi
    Matsubara, Saburo
    Ito, Yukiko
    Yamamoto, Natsuyo
    Sasahira, Naoki
    Hirano, Kenji
    Toda, Nobuo
    Tada, Minoru
    Koike, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [27] Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study
    Larsen, Finn Ole
    Markussen, Alice
    Diness, Laura V.
    Nielsen, Dorte
    ONCOLOGY, 2018, 94 (01) : 19 - 24
  • [28] An exploratory study of fruquintinib as second-line treatment for patients with advanced or metastatic biliary tract cancer.
    Li, Qiu
    Zhang, Pengfei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A Retrospective Study of Gemcitabine and Cisplatin Combination Therapy as Second-Line Treatment for Advanced Biliary Tract Cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Takahara, Naminatsu
    Akiyama, Dai
    Yagioka, Hiroshi
    Kogure, Hirofumi
    Matsubara, Saburo
    Ito, Yukiko
    Yamamoto, Natsuyo
    Sasahira, Naoki
    Hirano, Kenji
    Toda, Nobuo
    Tada, Minoru
    Koike, Kazuhiko
    CHEMOTHERAPY, 2013, 59 (02) : 106 - 111
  • [30] A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
    Zheng, Yi
    Tu, Xiaoxuan
    Zhao, Peng
    Jiang, Weiqin
    Liu, Lulu
    Tong, Zhou
    Zhang, Hangyu
    Yan, Cong
    Fang, Weijia
    Wang, Weilin
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 291 - 295
12345